Role of Erbin in ErbB2-dependent breast tumor growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 42, 2014, Pages E4429-E4438

  Tao, Yanmei ^a,b   Shen, Chengyong ^a   Luo, Shiwen ^c   Traoré, Wilfried ^d,e,f,g   Marchetto, Sylvie ^d,e,f,g   Santoni, Marie Josée ^d,e,f,g   Xu, Linlin ^c   Wu, Biao ^c   Shi, Chao ^c   Mei, Jinghong ^c   Bates, Ryan ^a   Liu, Xihui ^a   Zhao, Kai ^a   Xiong, Wen Cheng ^a   Borg, Jean Paul ^d,e,f,g   Mei, Lin ^a,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b HANGZHOU NORMAL UNIVERSITY   (China)

^c NANCHANG UNIVERSITY   (China)

^d INSERM   (France)

^e INSTITUT PAOLI CALMETTES   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Breast cancer; ErbB2; Erbin; HSP90; Stability

Indexed keywords

CYTOPLASM PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90; PROTEIN ERBIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; ERBB2 PROTEIN, HUMAN; ERBB2 PROTEIN, MOUSE; ERBB2IP PROTEIN, HUMAN; ERBB2IP PROTEIN, MOUSE; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CARCINOGENESIS; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; MOLECULAR STABILITY; MOUSE; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PDZ DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; ADULT; ANIMAL; BREAST TUMOR; CELL TRANSFORMATION; DISEASE COURSE; EXPERIMENTAL MAMMARY NEOPLASM; GENE DELETION; GENE SILENCING; HEK293 CELL LINE; HUMAN; METABOLISM; MIDDLE AGED; MUTATION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; FEMALE; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; MIDDLE AGED; MUTATION; PROTEIN BINDING; RECEPTOR, ERBB-2;

EID: 84908065149     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1407139111     Document Type: Article

References (53)

1. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269-280.
2. Yu D, Hung MC (2000) Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19(53):6115-6121.
3. Slamon DJ, et al. (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707-712.
4. Yarden Y, Pines G (2012) The ERBB network: At last, cancer therapy meets systems biology. Nat Rev Cancer 12(8):553-563.
5. Guy CT, et al. (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89(22):10578-10582.
6. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54(1):105-115.
7. Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G (1996) All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem 271(9):5251-5257.
8. Lenferink AE, et al. (1998) Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J 17(12):3385-3397.
9. Bilder D, Perrimon N (2000) Localization of apical epithelial determinants by the basolateral PDZ protein Scribble. Nature 403(6770):676-680.
10. Santoni MJ, Pontarotti P, Birnbaum D, Borg JP (2002) The LAP family: A phylogenetic point of view. Trends Genet 18(10):494-497.
11. Borg JP, et al. (2000) ERBIN: A basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol 2(7):407-414.
12. Huang YZ, Wang Q, Xiong WC, Mei L (2001) Erbin is a protein concentrated at post-synaptic membranes that interacts with PSD-95. J Biol Chem 276(22):19318-19326.
13. Dai F, et al. (2007) Erbin inhibits transforming growth factor beta signaling through a novel Smad-interacting domain. Mol Cell Biol 27(17):6183-6194.
14. Dai P, Xiong WC, Mei L (2006) Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. J Biol Chem 281(2):927-933.
15. Huang YZ, Zang M, Xiong WC, Luo Z, Mei L (2003) Erbin suppresses the MAP kinase pathway. J Biol Chem 278(2):1108-1114.
16. Dardousis K, et al. (2007) Identification of differentially expressed genes involved in the formation of multicellular tumor spheroids by HT-29 colon carcinoma cells. Mol Ther 15(1):94-102.
17. Anastasiadis PZ, Reynolds AB (2000) The p120 catenin family: Complex roles in adhesion, signaling and cancer. J Cell Sci 113(Pt 8):1319-1334.
18. Tao Y, et al. (2009) Erbin regulates NRG1 signaling and myelination. Proc Natl Acad Sci USA 106(23):9477-9482.
19. Herschkowitz JI, et al. (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8(5):R76.
20. Desai KV, et al. (2002) Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 99(10):6967-6972.
21. Guy CT, Cardiff RD, Muller WJ (1992) Induction of mammary tumors by expression of polyomavirus middle T oncogene: A transgenic mouse model for metastatic disease. Mol Cell Biol 12(3):954-961.
22. Kao J, Pollack JR (2006) RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes Chromosomes Cancer 45(8):761-769.
23. Neve RM, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515-527.
24. Tao Y, et al. (2013) Erbin interacts with TARP γ-2 for surface expression of AMPA receptors in cortical interneurons. Nat Neurosci 16(3):290-299.
25. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS (2001) ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3(9):785-792.
26. Izawa I, Nishizawa M, Hayashi Y, Inagaki M (2008) Palmitoylation of ERBIN is required for its plasma membrane localization. Genes Cells 13(7):691-701.
27. Legouis R, et al. (2003) Basolateral targeting by leucine-rich repeat domains in epithelial cells. EMBO Rep 4(11):1096-1102.
28. Lu S, Simin K, Khan A, Mercurio AM (2008) Analysis of integrin beta4 expression in human breast cancer: Association with basal-like tumors and prognostic significance. Clin Cancer Res 14(4):1050-1058.
29. Xie W, et al. (2002) Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Res 62(2):497-505.
30. Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4(6):470-480.
31. Xu W, et al. (2001) Sensitivity of mature Erbb2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J Biol Chem 276(5):3702-3708.
32. Xu W, Mimnaugh EG, Kim JS, Trepel JB, Neckers LM (2002) Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. Cell Stress Chaperones 7(1):91-96.
33. Zhou P, et al. (2003) ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 278(16):13829-13837.
34. Xu W, Yuan X, Beebe K, Xiang Z, Neckers L (2007) Loss of Hsp90 association upregulates Src-dependent ErbB2 activity. Mol Cell Biol 27(1):220-228.
35. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285(5433):1569-1572.
36. Baselga J, et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14(3):737-744.
37. Cobleigh MA, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9):2639-2648.
38. Agus DB, et al. (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2):127-137.
39. Geyer CE, et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355(26):2733-2743.
40. Abramson V, Arteaga CL (2011) New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available. Clin Cancer Res 17(5):952-958.
41. Scaltriti M, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99(8):628-638.
42. Lerdrup M, et al. (2007) Endocytic down-regulation of ErbB2 is stimulated by cleavage of its C-terminus. Mol Biol Cell 18(9):3656-3666.
43. Magnifico A, et al. (2007) Protein kinase Calpha determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification. Cancer Res 67(11):5308-5317.
44. Vernimmen D, Gueders M, Pisvin S, Delvenne P, Winkler R (2003) Different mechanisms are implicated in ERBB2 gene overexpression in breast and in other cancers. Br J Cancer 89(5):899-906.
45. Austin CD, et al. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15(12):5268-5282.
46. Xu W, et al. (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci USA 99(20):12847-12852.
47. Shelly M, et al. (2003) Polar expression of ErbB-2/HER2 in epithelia. Bimodal regulation by Lin-7. Dev Cell 5(3):475-486.
48. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10(8):537-549.
49. Pust S, et al. (2013) Flotillins as regulators of ErbB2 levels in breast cancer. Oncogene 32(29):3443-3451.
50. Schulz R, et al. (2012) Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med 209(2):275-289.
51. Ellis IO, et al. (2003) Pathology and genetics of tumours of the breast and female genital organs. World Health Organization Classification of Tumours, eds Tavassoli F, Devilee P, (WHO, Geneva), pp 14-41.
52. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19(5):403-410.
53. Robbins P, et al. (1995) Histological grading of breast carcinomas: A study of interobserver agreement. Hum Pathol 26(8):873-879.